Agonist News and Research

RSS

PhaseBio commences Glymera Phase 2b study in type 2 diabetes

PhaseBio Pharmaceuticals, Inc., a privately held, clinical-stage biotechnology company developing drugs to treat diabetes, metabolic disease and cardiovascular disease, announced today that it has initiated dosing in a multicenter (USA), randomized, placebo and active comparator controlled Phase 2b study that will enroll approximately 600 patients with type 2 diabetes (hemoglobin A1c 7% - 11%) inadequately controlled with diet and exercise, metformin, a sulfonylurea or a combination of metformin/sulfonylurea.

22 Aug 2012

Age, drugs, and disease alter sleep in Parkinson’s disease

Sleep patterns in patients with Parkinson’s disease are affected by age, disease severity, and dopamine agonists, German research indicates.

17 Aug 2012

Be alert for arrhythmias in new bronchodilator patients, researchers say

Chronic obstructive pulmonary disease patients should be monitored for the onset of arrhythmia when they begin bronchodilator therapy, say the authors of a Canadian study.

14 Aug 2012

Two-drug combination helps combat cocaine addiction

A combination of two existing pharmaceutical drugs may soon be used to treat cocaine addiction, findings from an animal study in Science Translational Medicine suggest.

10 Aug 2012

Combination of two existing pharmaceutical drugs shows promise against cocaine addiction

A fine-tuned combination of two existing pharmaceutical drugs has shown promise as a potential new therapy for people addicted to cocaine—a therapy that would reduce their craving for the drug and blunt their symptoms of withdrawal.

9 Aug 2012

GTx reports revenue of $1.6 million for second quarter 2012

GTx, Inc. today provided a Company update and reported financial results for the second quarter of 2012.

8 Aug 2012

USPTO issues patent to Aeterna Zentaris’ AEZS-130 oral test for AGHD

Aeterna Zentaris Inc. today announced that the United States Patent and Trademark Office has granted a patent for the use of its oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency.

7 Aug 2012

Mechanism provides beneficial characteristics of energy-burning brown fat to white fat

Columbia University Medical Center (CUMC) researchers have identified a mechanism that can give energy-storing white fat some of the beneficial characteristics of energy-burning brown fat. The findings, based on studies of mice and of human fat tissue, could lead to new strategies for treating obesity and type 2 diabetes.

3 Aug 2012

Treatments for peripheral neuropathic pain compared

The first study to compare the 8% capsaicin patch with pregabalin as a treatment for peripheral neuropathic pain begins, with enrolment of the first patient.

31 Jul 2012

Study identifies Olympic athletes with asthma and airway hyper-responsiveness

Based on data from the last five Olympic games, a study by the University of Western Australia has identified those athletes with asthma and airway hyper-responsiveness. With a prevalence of around 8% they are the most common chronic conditions among Olympic athletes, and could be related to intense training.

31 Jul 2012

Aeterna Zentaris files request with FDA for Fast Track designation for AEZS-130

Aeterna Zentaris Inc. today announced that it has filed a request with the United States Food and Drug Administration (FDA) for Fast Track designation for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD).

25 Jul 2012

Scientists identify mechanisms by which GLP-1 protects against kidney disease, diabetes

Scientists at Joslin Diabetes Center have identified biological mechanisms by which glucagon-like peptide-1 (GLP-1), a gut hormone, protects against kidney disease, and also mechanisms that inhibit its actions in diabetes.

24 Jul 2012

Abscisic acid has anti-inflammatory effects in the lungs and gut

Building on previous work with the botanical abscisic acida, researchers in the Nutritional Immunology and Molecular Medicine Laboratory (NIMML) have discovered that abscisic acid has anti-inflammatory effects in the lungs as well as in the gut.

19 Jul 2012

Mu-opioid receptors put brakes on appetite

Activation of mu-opioid receptors in the nerves of the portal vein walls triggers a gut–brain neural circuit that leads to feelings of satiety, researchers report in Cell.

17 Jul 2012

UCB’s Neupro now available in U.S. pharmacies

UCB announced today that Neupro (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro was approved by the U.S Food and Drug Administration in April to treat the signs and symptoms of early and advanced stage idiopathic Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome.

16 Jul 2012

Lesogaberan development halts following disappointing results

Lesogaberan is only marginally superior to placebo in gastroesophageal reflux disease patients who are partially responsive to proton pump inhibitor therapy, results show.

10 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

New strategy to reduce or eliminate scars on the skin

Whether from surgery or battle wounds, ugly scars can affect body and mind. Now a new research report appearing online in the FASEB Journal offers a new strategy to reduce or eliminate scars on the skin.

7 Jul 2012

FDA action affects companies that manufacture and distribute unapproved oxycodone drugs

The U.S. Food and Drug Administration today issued a Federal Register notice instructing companies to stop manufacturing and distributing certain unapproved drugs that contain oxycodone. The notice is part of the FDA's Unapproved Drugs Initiative to remove unapproved new drugs from the market.

6 Jul 2012

Imaging PR status may help identify tumor response to endocrine therapy

Research published in the July issue of The Journal of Nuclear Medicine shows imaging progesterone receptor (PR) status also may be able to identify responders and nonresponders to endocrine therapy at an early stage.

3 Jul 2012